Body weight loss after surgery affects the continuity of adjuvant chemotherapy for pancreatic cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Body weight loss after surgery affects the continuity of adjuvant chemotherapy for pancreatic cancer ; volume:19 ; number:1 ; day:2 ; month:5 ; year:2019 ; pages:1-10 ; date:12.2019
BMC cancer ; 19, Heft 1 (2.5.2019), 1-10, 12.2019
- Klassifikation
-
Medizin, Gesundheit
- Urheber
-
Morita, Yoshifumi
Sakaguchi, Takanori
Kitajima, Ryo
Furuhashi, Satoru
Kiuchi, Ryota
Takeda, Makoto
Hiraide, Takanori
Shibasaki, Yasushi
Kikuchi, Hirotoshi
Konno, Hiroyuki
Takeuchi, Hiroya
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-019-5621-5
- URN
-
urn:nbn:de:101:1-2019052123014955102018
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Morita, Yoshifumi
- Sakaguchi, Takanori
- Kitajima, Ryo
- Furuhashi, Satoru
- Kiuchi, Ryota
- Takeda, Makoto
- Hiraide, Takanori
- Shibasaki, Yasushi
- Kikuchi, Hirotoshi
- Konno, Hiroyuki
- Takeuchi, Hiroya
- SpringerLink (Online service)
Ähnliche Objekte (12)
Adjuvant chemotherapy omission after pancreatic cancer resection: a French nationwide study
Necroptosis participates in the responsiveness of neo-adjuvant chemotherapy in pancreatic adenocarcinoma
Adjuvant chemotherapy after surgery for pancreatic ductal adenocarcinoma: retrospective real-life data
Adjuvant chemotherapy in pancreatic cancer at different AJCC stages: a propensity score matching analysis
Gemcitabine-Induced Cardiotoxicity in Patients Receiving Adjuvant Chemotherapy for Pancreatic Cancer: A Case Series
Adjuvant Chemotherapy Associated with Survival Benefit Following Neoadjuvant Chemotherapy and Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Population-Based Cohort Study
Strong prognostic value of nodal microinvolvement in patients with pancreatic ductal carcinoma receiving no adjuvant chemotherapy
hENT1’s role in adjuvant intra-arterial gemcitabine-based chemotherapy for resectable pancreatic cancer patients
Adjuvant Chemotherapy for Epithelial Ovarian Cancer (EOC)
Impact of adjuvant chemotherapy for gliomatosis cerebri
Impact of ERAS compliance on the delay between surgery and adjuvant chemotherapy in hepatobiliary and pancreatic malignancies
Comparison of 4- and 4 plus-courses S-1 administration as adjuvant chemotherapy for pancreatic ductal adenocarcinoma
Adjuvant chemotherapy omission after pancreatic cancer resection: a French nationwide study
Necroptosis participates in the responsiveness of neo-adjuvant chemotherapy in pancreatic adenocarcinoma
Adjuvant chemotherapy after surgery for pancreatic ductal adenocarcinoma: retrospective real-life data
Adjuvant chemotherapy in pancreatic cancer at different AJCC stages: a propensity score matching analysis
Gemcitabine-Induced Cardiotoxicity in Patients Receiving Adjuvant Chemotherapy for Pancreatic Cancer: A Case Series
Adjuvant Chemotherapy Associated with Survival Benefit Following Neoadjuvant Chemotherapy and Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Population-Based Cohort Study
Strong prognostic value of nodal microinvolvement in patients with pancreatic ductal carcinoma receiving no adjuvant chemotherapy
hENT1’s role in adjuvant intra-arterial gemcitabine-based chemotherapy for resectable pancreatic cancer patients
Adjuvant Chemotherapy for Epithelial Ovarian Cancer (EOC)
Impact of adjuvant chemotherapy for gliomatosis cerebri
Impact of ERAS compliance on the delay between surgery and adjuvant chemotherapy in hepatobiliary and pancreatic malignancies
Comparison of 4- and 4 plus-courses S-1 administration as adjuvant chemotherapy for pancreatic ductal adenocarcinoma
Adjuvant chemotherapy omission after pancreatic cancer resection: a French nationwide study
Necroptosis participates in the responsiveness of neo-adjuvant chemotherapy in pancreatic adenocarcinoma
Adjuvant chemotherapy after surgery for pancreatic ductal adenocarcinoma: retrospective real-life data
Adjuvant chemotherapy in pancreatic cancer at different AJCC stages: a propensity score matching analysis
Gemcitabine-Induced Cardiotoxicity in Patients Receiving Adjuvant Chemotherapy for Pancreatic Cancer: A Case Series
Adjuvant Chemotherapy Associated with Survival Benefit Following Neoadjuvant Chemotherapy and Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Population-Based Cohort Study
Strong prognostic value of nodal microinvolvement in patients with pancreatic ductal carcinoma receiving no adjuvant chemotherapy
hENT1’s role in adjuvant intra-arterial gemcitabine-based chemotherapy for resectable pancreatic cancer patients
Adjuvant Chemotherapy for Epithelial Ovarian Cancer (EOC)
Impact of adjuvant chemotherapy for gliomatosis cerebri
Impact of ERAS compliance on the delay between surgery and adjuvant chemotherapy in hepatobiliary and pancreatic malignancies